Navigation Links
Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
Date:7/9/2008

-- Dr. Fernando Perez-Ruiz Joins Ardea's Inflammatory Disease Scientific

Advisory Board --

SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has received regulatory approval to begin a Phase 2a proof-of-concept clinical trial evaluating RDEA806 in gout patients with hyperuricemia. Gout, also known as metabolic arthritis, is a painful and debilitating disease caused by abnormally elevated levels of uric acid in the blood stream, and is the most common form of inflammatory arthritis in men over 40. The Company also announced that gout specialist, Dr. Fernando Perez-Ruiz in Spain, will be the newest member of its inflammatory disease scientific advisory board (SAB).

Ardea previously announced the designation of RDEA594, a major metabolite of RDEA806, the Company's lead human immunodeficiency virus (HIV) development compound, as its lead development candidate for the treatment of patients with gout. RDEA594 does not have antiviral activity, but is believed to be responsible for essentially all of the uric acid lowering effects seen with RDEA806. Uric acid lowering effects have been observed following administration of RDEA806 in Phase 1 and Phase 2 clinical trials that included over 100 subjects.

"The Phase 2a trial should allow us to confirm RDEA594's activity in the target population of patients with gout using its prodrug, RDEA806. Enrollment in the Phase 2a trial should begin shortly and we are on track to initiate a Phase 1 trial with RDEA594 in the second half of this year," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We also are extremely pleased to add Dr. Fernando Perez-Ruiz to our inflammatory diseases S
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Craig Johnson Joins Ardea Biosciences Board of Directors
2. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
4. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
7. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
8. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
9. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
10. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
11. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BROOK, NY (PRWEB) July 30, 2014 ... APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based ... Michael E. Hogan, Ph.D. Vice President of Life Sciences, ... mid-September. , Dr. Hogan will lead APDN’s ... form business relationships with biotech and healthcare customers, provide ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... IRVINE, Calif. , July 30, 2014 /PRNewswire/ ... on the research and development of compounds to ... in humans, today announces that its partner, CardioNova, ... Phase 1b clinical trial with AtheroNova,s lead compound, ... continuation of the AHRO-001 Phase 1 safety trial ...
(Date:7/30/2014)... 2014 Vala Sciences was recently ... Protection Agency (EPA). This new contract was awarded ... including tests designed to assess the effect of ... of connections between neurons (synapses), which are critical ... formation by environmental pollutants likely contributes to a ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... historians, journalists and politicians, and has been recounted everywhere from ... forces used chemical weapons on Iraqis just after World War ... squared with the historical record, says R. M. Douglas, a ... the December issue of The Journal of Modern History ...
... at the University of East Anglia (UEA) could contribute ... agricultural waste to generate clean electricity. Published today ... National Academy of Sciences (PNAS), the researchers have ... some bacteria survive by ,breathing rocks,. The findings ...
... roadside bombs to freeway crashes. Traumatic injury, the leading cause ... the body,s natural blood-clotting process. In an effort to ... a new Case Western Reserve University biomedical engineering professor, and ... that show promise in halting internal and external bleeding. Their ...
Cached Biology Technology:Despite claims, UK did not gas Iraqis in the 1920s, new research finds 2Despite claims, UK did not gas Iraqis in the 1920s, new research finds 3Despite claims, UK did not gas Iraqis in the 1920s, new research finds 4'Rock-breathing' bacteria could generate electricity and clean up oil spills 2Researchers take the inside route to halt bleeding 2
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... of Engineering recently received a $330,000 award from ... synthesis of organic nanorods." , According to ... and utilization of functional materials, devices, and systems ... in scaling up nanotechnology is the lack of ... one device. A research team led by Dr. ...
(Date:7/30/2014)... treatment has been shown to relieve patients, pain. ... transmission between the peripheral and central nervous systems, ... Radiation Medicine, Chinese Academy of Medical Sciences, China ... dorsal root ganglia (DRG) to provide relief for ... 14.8, 29.6 MBq) were implanted separately into the ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... chemicals routinely added to consumer products from carpets to ... Health officials, however, are concerned that one class of ... more than reducing fire-related injuries and property damage. ... distributed in the environment as contaminants, and trace levels ...
... testing for adult-onset diseases, including cancer, is generally discouraged ... be helpful. Yet, many children of BRCA mutation ... years before preventive interventions are indicated. ... Clinical Oncology, describes the prevalence and experiences of parental ...
... PICK: Can cancer drugs combine forces? ... with a drug known as imatinib (Gleevec), which targets ... their disease returns, because BCR-ABL mutants emerge that are ... with a drug known as dasatinib (SPRYCEL), which targets ...
Cached Biology News:SRMs track fire retardants in humans and environment 2JCI table of contents: Aug. 16, 2007 2JCI table of contents: Aug. 16, 2007 3JCI table of contents: Aug. 16, 2007 4JCI table of contents: Aug. 16, 2007 5JCI table of contents: Aug. 16, 2007 6JCI table of contents: Aug. 16, 2007 7
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Recognizes Kir4.1. The epitope does not share homology with any other known proteins.,SPECIES REACTIVITIES: The antibody is also expected to work with mouse and human due to sequence homology. Oth...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: